China's updated ADR reporting rules to increase manufacturers' obligations
This article was originally published in SRA
Executive Summary
China's Ministry of Health has issued revised rules on the monitoring and reporting of adverse drug reactions1. The revised provisions will apply from 1 July and are likely to "significantly increase" the regulatory obligations of pharmaceutical manufacturers, according to legal experts at Sidley Austin2.
You may also be interested in...
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.
Global Medtech Guidance Tracker: March 2024
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-nine documents have been posted on the tracker since its last update.